Structure-function studies for in vitro chemical inhibition of Fcγ receptor-mediated phagocytosis

Transfusion

Volumn 47, Issue 2, 2007, Pages 290-298

  Foo, Alison H ^b   Fletcher, Stephen P ^b   Langler, Richard F ^b   Porter, Charlotte H ^b   Branch, Donald R ^a  

^a CANADIAN BLOOD SERVICES   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBONYL DERIVATIVE; CHLORNITROFEN; DISULFIDE; FC RECEPTOR; FUNCTIONAL GROUP; HYDROXYL GROUP; THIOL DERIVATIVE;

ARTICLE; CHEMICAL BOND; CYTOPENIA; ERYTHROCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MONOCYTE; PHAGOCYTOSIS;

ANTIBODIES; DISULFIDES; ERYTHROCYTES; HUMANS; MACROPHAGES; NITROBENZENES; NITROPHENOLS; PHAGOCYTOSIS; RECEPTORS, IGG; STRUCTURE-ACTIVITY RELATIONSHIP; SULFHYDRYL COMPOUNDS;

EID: 33846434459     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01105.x     Document Type: Article

References (39)

1. Schmidt RE, Gessner JE. Fc receptors and their interaction with complement in autoimmunity. Immunol Lett 2005;100:56-67.
2. Rampersad G, Suck G, Sakac D, et al. Chemical compounds that target thiol/disulfide groups on mononuclear phagocytes inhibit immune mediated phagocytosis of red blood cells. Transfusion 2005;45:384-93.
3. Baerlocher FJ, Baerlocher MO, Langler RF, MacQuarrie SL, Marchand ME. New and more potent antifungal disulfides. Aust J Chem 2000;53:1-5.
4. Griffiths R, Wong WW, Fletcher SP, Penn LZ, Langler RF. Novel disulfides with antitumor efficacy and specificity. Aust J Chem 2005;58:128-36.
5. +. Aust J Chem 2005;58:362-7.
6. Kabir SM, Langler RF, Smith RD, Tam NC, Webb JD. Accelerating column chromatography: the bundled approach. J Sulfur Chem, 2005;26:7-11.
7. Walker RF, Branch DR, Dzik WH, et al. Mononuclear phagocyte assay. 11th ed. Bethesda: American Association of Blood Banks; 1993.
8. Branch DR, Gallagher MT, Mison AP, Sy Siok Hian AL, Petz LD. In vitro determination of red cell alloantibody significance using an assay of monocyte-macrophage interaction with sensitized erythrocytes. Br J Haematol 1984;56:19-29.
9. Gaines AR. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood 2000;95:2523-9.
10. Knezevic-Maramica I, Kruskall M. Intravenous immune globulins: an update for clinicians. Transfusion 2003;43:1460-72.
11. Barandun S, Isliker H. Development of immunoglobulin preparations for intravenous use. Vox Sang 1986;51:157-60.
12. Bleeker WK, Teeling JL, Verhoeven AJ, et al. Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase. Blood 2000;95:1856-61.
13. Barandun S, Kistler P, Jeunet F, Isliker H. Intravenous administration of human γ-globulin. Vox Sang 1962;7:157-64.
14. Epstein JS, Zoon KC. Letter to healthcare providers. Important drug warning: immune globulin intravenous (human). Washington (DC): Center for Biologics Evaluation and Research, Food and Drug Administration; 1998 Nov 13.
15. Sekul E, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994;121:259-62.
16. Go RS, Call TG. Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 2000;75:83-5.
17. Elkayam O, Paran D, Milo R, et al. Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders: a study of four cases. Ann Rheum Dis 2000;59:77-80.
18. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994;44:223-6.
19. Harkness KA, Goulding P. Central retinal vein occlusion complicating treatment with intravenous immunoglobulin. Eye 2000;14:662-3.
20. Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 1986;2:217-8.
21. Silbert PL, Knezevic WV, Bridge D. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 1992;42:257-8.
22. Wolff SN, Fay JW, Herzig RH, et al. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy: a study of the American Bone Marrow Transplant Group. Ann Intern Med 1993;118:937-42.
23. Sandler SG, Mallory D, Eckrich R. IgA anaphylactic transfusion reactions. Transfus Med Rev 1995;9:1-8.
24. Nydegger UE, Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. J Clin Immunol 2000;20:77-82.
25. Milgrom H. Shortage of intravenous immunoglobulin. Ann Allergy Asthma Immunol 1998;81:97-100.
26. Yap PL. The viral safety of intravenous immune globulin. Clin Exp Immunol 1996;104(Suppl 1):35-42.
27. Kong G, Kain KC, Crandall I, Langler RF. Novel disulfides as anticancer/antimalarial agents. Sulfur Lett 2003;26:149-54.
28. Wong WW, MacDonald S, Langler RF, Penn LZ. Novel synthetic organosulfur compounds induce apoptosis of human leukemic cells. Anticancer Res 2000;20:1367-74.
29. MacDonald JA, Langler RF. Structure-activity relationships for selected sulfur-rich antithrombotic compounds. Biochem Biophys Res Commun 2000;273:421-4.
30. MacDonald JA, Marchand ME, Langler RF. Improving upon the in vitro biological activity of antithrombotic disulfides. Blood Coagul Fibrinolysis 2004;15:447-50.
31. Langler RF, McNamara RA, O'Connor PE, MacQuarrie SL. A new synthesis for antifungal a-sulfone disulfides. Aust J Chem 1999;52:1119-21.
32. 2 oxygen atoms are essential for the pronounced fungitoxicity of the sulfurrich natural product, dysoxysulfone. Aust J Chem 2005;58:218-23.
33. Andersen J, Langler RF, Baerlocher FJ. Phylum-specific fungitoxicity of new disulfide compounds. Sydowia 2002;54:121-8.
34. Baerlocher FJ, Baerlocher MO, Langler RF, MacQuarrie SL, O'Connor PE. Optimizing disulfide fungitoxicity: adjustment of hydrocarbon chain length. Sulfur Lett 2002;25:135-44.
35. Baerlocher FJ, Baerlocher MO, Guckert KD, et al. Selected α,α-dimethyl disulfides: submicrogram fungitoxins. Aust J Chem 2001;54:397-400.
36. Baerlocher FJ, Baerlocher MO, Chaulk CL, Langler RF, O'Brien EM. New antifungal disulfides: approaching submicrogram toxicity. Sulfur Lett 2000;24:101-7.
37. Baerlocher FJ, Langler RF, Frederiksen MU, Georges NM, Witherell RD. Structure-activity relationships for selected sulfur-rich antifungal compounds. Aust J Chem 1999;52:167-72.
38. Baum JC, Bolhassan J, Langler RF, Pujol PJ, Raheja RK. Sulfonyl esters 2. CS cleavage in some substitution reactions of nitrobenzenesulfonates. Can J Chem 1990;68:1450-5.
39. Crow AR, Song S, Semple JW, Freedman J, Lazarus AH. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Br J Haematol 2001;115:679-86.